BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 10463605)

  • 1. Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel.
    Yamori T; Matsunaga A; Sato S; Yamazaki K; Komi A; Ishizu K; Mita I; Edatsugi H; Matsuba Y; Takezawa K; Nakanishi O; Kohno H; Nakajima Y; Komatsu H; Andoh T; Tsuruo T
    Cancer Res; 1999 Aug; 59(16):4042-9. PubMed ID: 10463605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel synthetic DNA minor groove binder, MS-247: antitumor activity and cytotoxic mechanism.
    Matsuba Y; Edatsugi H; Mita I; Matsunaga A; Nakanishi O
    Cancer Chemother Pharmacol; 2000; 46(1):1-9. PubMed ID: 10912571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.
    Hartley JA; Spanswick VJ; Brooks N; Clingen PH; McHugh PJ; Hochhauser D; Pedley RB; Kelland LR; Alley MC; Schultz R; Hollingshead MG; Schweikart KM; Tomaszewski JE; Sausville EA; Gregson SJ; Howard PW; Thurston DE
    Cancer Res; 2004 Sep; 64(18):6693-9. PubMed ID: 15374986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor agents. 194. Synthesis and biological evaluations of 4-beta-mono-, -di-, and -trisubstituted aniline-4'-O-demethyl-podophyllotoxin and related compounds with improved pharmacological profiles.
    Zhu XK; Guan J; Tachibana Y; Bastow KF; Cho SJ; Cheng HH; Cheng YC; Gurwith M; Lee KH
    J Med Chem; 1999 Jul; 42(13):2441-6. PubMed ID: 10395485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
    Pratesi G; De Cesare M; Carenini N; Perego P; Righetti SC; Cucco C; Merlini L; Pisano C; Penco S; Carminati P; Vesci L; Zunino F
    Clin Cancer Res; 2002 Dec; 8(12):3904-9. PubMed ID: 12473606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Camptothecin conjugated with DNA minor-groove binder netropsin: enhanced lactone stability, inhibition of human DNA topoisomerase I and antiproliferative activity.
    Sukhanova A; Grokhovsky S; Zhuze A; Devy J; Pluot M; Oleinikov V; Nabiev I
    Anticancer Res; 2003; 23(3B):2609-15. PubMed ID: 12894548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics.
    Yamori T
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S74-9. PubMed ID: 12819939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of antitumor activity of KW-2189, a novel water-soluble derivative of duocarmycin, against murine and human tumors.
    Kobayashi E; Okamoto A; Asada M; Okabe M; Nagamura S; Asai A; Saito H; Gomi K; Hirata T
    Cancer Res; 1994 May; 54(9):2404-10. PubMed ID: 8162588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo.
    Hjarnaa PJ; Jonsson E; Latini S; Dhar S; Larsson R; Bramm E; Skov T; Binderup L
    Cancer Res; 1999 Nov; 59(22):5751-7. PubMed ID: 10582695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of fluorenhymustine as a rationally designed novel anticancer agent.
    Samanta S; Pain A; Ghosh M; Dutta S; Sanyal U
    Exp Oncol; 2005 Dec; 27(4):279-85. PubMed ID: 16404347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel antitumor indenoindole derivatives targeting DNA and topoisomerase II.
    Bal C; Baldeyrou B; Moz F; Lansiaux A; Colson P; Kraus-Berthier L; Léonce S; Pierré A; Boussard MF; Rousseau A; Wierzbicki M; Bailly C
    Biochem Pharmacol; 2004 Nov; 68(10):1911-22. PubMed ID: 15476662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical antitumor activity of bizelesin in mice.
    Carter CA; Waud WR; Li LH; DeKoning TF; McGovren JP; Plowman J
    Clin Cancer Res; 1996 Jul; 2(7):1143-9. PubMed ID: 9816280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brostallicin (PNU-166196), a new minor groove DNA binder: preclinical and clinical activity.
    Lorusso D; Mainenti S; Pietragalla A; Ferrandina G; Foco G; Masciullo V; Scambia G
    Expert Opin Investig Drugs; 2009 Dec; 18(12):1939-46. PubMed ID: 19938904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor efficacy and molecular mechanism of TLK58747, a novel DNA-alkylating prodrug.
    Xu H; Wang Z; Donaldson JC; Yao H; Zhou S; Kelson AB; Ma W; Weber KT; Laborde E; Cheng M; Sambucetti L; Keck JG
    Anticancer Res; 2009 Oct; 29(10):3845-55. PubMed ID: 19846918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners.
    Beria I; Baraldi PG; Cozzi P; Caldarelli M; Geroni C; Marchini S; Mongelli N; Romagnoli R
    J Med Chem; 2004 May; 47(10):2611-23. PubMed ID: 15115402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.
    Tanno B; Mancini C; Vitali R; Mancuso M; McDowell HP; Dominici C; Raschellà G
    Clin Cancer Res; 2006 Nov; 12(22):6772-80. PubMed ID: 17121898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor properties of some 2-[(dimethylamino)methyl]phenylgold(III) complexes.
    Buckley RG; Elsome AM; Fricker SP; Henderson GR; Theobald BR; Parish RV; Howe BP; Kelland LR
    J Med Chem; 1996 Dec; 39(26):5208-14. PubMed ID: 8978849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and in vitro and in vivo antitumor activity of 2-phenylpyrroloquinolin-4-ones.
    Ferlin MG; Chiarelotto G; Gasparotto V; Dalla Via L; Pezzi V; Barzon L; Palù G; Castagliuolo I
    J Med Chem; 2005 May; 48(9):3417-27. PubMed ID: 15857148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic and antitumoral activity of phenyl-3-(2-chloroethyl)ureas: a class of soft alkylating agents disrupting microtubules that are unaffected by cell adhesion-mediated drug resistance.
    Petitclerc E; Deschesnes RG; Côté MF; Marquis C; Janvier R; Lacroix J; Miot-Noirault E; Legault J; Mounetou E; Madelmont JC; C -Gaudreault R
    Cancer Res; 2004 Jul; 64(13):4654-63. PubMed ID: 15231678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.